Secondary malignant neoplasm of cerebral meninges
ICD-10 C79.32 is a billable code used to indicate a diagnosis of secondary malignant neoplasm of cerebral meninges.
C79.32 refers to a secondary malignant neoplasm of the cerebral meninges, indicating that cancer has metastasized to the protective membranes covering the brain. This condition often arises from primary tumors located elsewhere in the body, such as lung, breast, or melanoma. The presence of metastatic disease in the meninges can lead to various neurological symptoms, including headaches, seizures, and cognitive changes. Diagnosis typically involves imaging studies like MRI or CT scans, which can reveal lesions on the meninges. Treatment options may include radiation therapy, chemotherapy, or palliative care, depending on the extent of the disease and the patient's overall health. Accurate coding is crucial for proper treatment planning and reimbursement, as well as for tracking the incidence of metastatic disease in clinical settings.
Detailed history of the primary cancer, treatment history, and current status of metastatic disease.
Patients with known primary cancers presenting with neurological symptoms.
Ensure that the primary site is documented to support the use of C79.32.
Neurological assessments, imaging results, and treatment plans.
Patients presenting with headaches, seizures, or cognitive decline.
Document neurological findings thoroughly to support the diagnosis.
Used when planning radiation therapy for meningeal metastases.
Detailed treatment plan and imaging results.
Oncology specialists should ensure accurate coding for treatment planning.
Accurate coding of C79.32 is crucial for appropriate treatment planning, reimbursement, and tracking the incidence of metastatic disease. It ensures that patients receive the necessary care and that healthcare providers are compensated for their services.
